DK3272338T3 - Oral doseringsform for ketamin - Google Patents

Oral doseringsform for ketamin Download PDF

Info

Publication number
DK3272338T3
DK3272338T3 DK17186622.1T DK17186622T DK3272338T3 DK 3272338 T3 DK3272338 T3 DK 3272338T3 DK 17186622 T DK17186622 T DK 17186622T DK 3272338 T3 DK3272338 T3 DK 3272338T3
Authority
DK
Denmark
Prior art keywords
ketamin
dosage form
oral dosage
oral
dosage
Prior art date
Application number
DK17186622.1T
Other languages
English (en)
Inventor
Sascha Manthei
Helene Rey
Marc Fischer
Olaf Mundszinger
Original Assignee
Develco Pharma Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develco Pharma Schweiz Ag filed Critical Develco Pharma Schweiz Ag
Application granted granted Critical
Publication of DK3272338T3 publication Critical patent/DK3272338T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17186622.1T 2014-04-17 2015-04-16 Oral doseringsform for ketamin DK3272338T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14165057 2014-04-17
EP15715764.5A EP3131533B1 (en) 2014-04-17 2015-04-16 Oral dosage form of ketamine

Publications (1)

Publication Number Publication Date
DK3272338T3 true DK3272338T3 (da) 2020-11-02

Family

ID=50486823

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17186622.1T DK3272338T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin
DK15715764.5T DK3131533T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15715764.5T DK3131533T3 (da) 2014-04-17 2015-04-16 Oral doseringsform for ketamin

Country Status (8)

Country Link
US (3) US10335379B2 (da)
EP (4) EP3287124B1 (da)
DK (2) DK3272338T3 (da)
ES (3) ES2829279T3 (da)
FI (1) FI3287124T3 (da)
HU (3) HUE060851T2 (da)
PL (3) PL3287124T3 (da)
WO (1) WO2015158854A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US10335379B2 (en) * 2014-04-17 2019-07-02 Develco Pharma Schweiz Ag Oral dosage forms of ketamine
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
CA3020681A1 (en) 2016-04-11 2017-10-19 Clexio Biosciences Ltd. Deuterated ketamine derivatives
EP3641742A2 (en) 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
RU2020123893A (ru) 2017-12-22 2022-01-24 Янссен Фармасьютикалз, Инк. Эскетамин для лечения депрессии
CA3113198A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
BR112021017457A2 (pt) 2019-03-05 2021-11-16 Janssen Pharmaceuticals Inc Escetamina para o tratamento de depressão
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
GB2596592A (en) 2020-07-03 2022-01-05 Alkaloid Ad Skopje Pharmaceutical formulation
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723614A (en) * 1971-01-06 1973-03-27 Ciba Geigy Ag Maltese-cross scored tablet
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7638651B2 (en) 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
US20120225949A1 (en) * 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
US20140079740A1 (en) * 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
CA2922507C (en) * 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
US10335379B2 (en) * 2014-04-17 2019-07-02 Develco Pharma Schweiz Ag Oral dosage forms of ketamine

Also Published As

Publication number Publication date
PL3131533T3 (pl) 2019-12-31
US20210386691A1 (en) 2021-12-16
EP3287124A1 (en) 2018-02-28
US11103467B2 (en) 2021-08-31
PL3287124T3 (pl) 2023-02-20
US20190290600A1 (en) 2019-09-26
HUE051264T2 (hu) 2021-03-01
US10335379B2 (en) 2019-07-02
HUE060851T2 (hu) 2023-04-28
EP3287124B1 (en) 2022-11-30
WO2015158854A1 (en) 2015-10-22
ES2935800T3 (es) 2023-03-10
US20170035707A1 (en) 2017-02-09
EP3131533A1 (en) 2017-02-22
DK3131533T3 (da) 2019-09-16
ES2829279T3 (es) 2021-05-31
FI3287124T3 (fi) 2023-01-13
EP3272338B1 (en) 2020-09-09
ES2743699T3 (es) 2020-02-20
EP4180030A1 (en) 2023-05-17
EP3131533B1 (en) 2019-06-05
PL3272338T3 (pl) 2021-01-11
EP3272338A1 (en) 2018-01-24
HUE044928T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
DK3272338T3 (da) Oral doseringsform for ketamin
ZA201700301B (en) Solid oral dosage form of lipophilic compounds
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
DK3363428T3 (da) Perfusionsdoseringsform
DK3199161T3 (da) Farmaceutisk præparat
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3126791T3 (da) Doseringsanordning
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
ZA201700843B (en) Oral pharmaceutical composition of isotretinoin
FR3024647B1 (fr) Transat de puericulture
DK3089740T3 (da) Farmaceutisk sammensætning
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
TH1501007601A (th) ส่วนผสมสำหรับใช้ในช่องปาก
TH1501005760A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1501005765A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1501004634A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1601000318A (th) สารประกอบเเละวิธีการเพื่อการสะสมเเร่ธาตุทางทันตกรรม
UA28473S (uk) Іригатор для догляду за ротовою порожниною
TH1601002230B (th) องค์ประกอบของยาสีฟัน